|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
674,040,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$17.15 - $26.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Avantor is a global manufacturer and distributor that provides products and services to customers in the biopharmaceutical, healthcare, education and government and advanced technologies and applied materials industries. Co.'s portfolio includes: Materials and consumables, such as lab products and supplies, formulated silicone materials, customized excipients, and customized single-use assemblies; equipment and instrumentation, such as filtration systems, virus inactivation systems, and incubators; and services and specialty procurement, such as onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
27,500 |
Total Buy Value |
$0 |
$0 |
$0 |
$573,100 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
27,872 |
27,872 |
60,449 |
163,424 |
Total Sell Value |
$687,456 |
$687,456 |
$1,380,595 |
$4,309,849 |
Total People Sold |
3 |
3 |
4 |
5 |
Total Sell Transactions |
4 |
4 |
6 |
15 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Couturier Christophe |
EVP, AMEA |
|
2023-02-28 |
4 |
AS |
$24.32 |
$56,520 |
D/D |
(2,324) |
100,717 |
|
-15% |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2023-02-27 |
4 |
AS |
$25.00 |
$76,475 |
D/D |
(3,059) |
112,629 |
|
-15% |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2023-02-25 |
4 |
D |
$24.62 |
$50,225 |
D/D |
(2,040) |
115,688 |
|
- |
|
Vanderhaegen Frederic |
EVP, Americas and Europe |
|
2023-02-25 |
4 |
D |
$24.62 |
$7,361 |
D/D |
(299) |
187,945 |
|
- |
|
Stubblefield Michael |
President & CEO |
|
2023-02-25 |
4 |
D |
$24.62 |
$189,205 |
D/D |
(7,685) |
1,279,137 |
|
- |
|
Eck Steven W |
SVP & Chief Accounting Officer |
|
2023-02-25 |
4 |
D |
$24.62 |
$12,433 |
D/D |
(505) |
21,733 |
|
- |
|
Bramwell James |
EVP, Americas |
|
2023-02-25 |
4 |
D |
$24.62 |
$12,581 |
D/D |
(511) |
104,310 |
|
- |
|
Henson Meghan |
EVP, Chief HR Officer |
|
2023-02-25 |
4 |
D |
$24.62 |
$19,696 |
D/D |
(800) |
40,184 |
|
- |
|
Lewis Sheri |
EVP, Global Ops & Supply Chain |
|
2023-02-25 |
4 |
D |
$24.62 |
$32,991 |
D/D |
(1,340) |
75,248 |
|
- |
|
Couturier Christophe |
EVP, AMEA |
|
2023-02-25 |
4 |
D |
$24.62 |
$11,498 |
D/D |
(467) |
103,041 |
|
- |
|
Szlosek Thomas A |
EVP & CFO |
|
2023-02-25 |
4 |
D |
$24.62 |
$50,225 |
D/D |
(2,040) |
104,853 |
|
- |
|
Miller Justin |
EVP & General Counsel |
|
2023-02-25 |
4 |
D |
$24.62 |
$13,787 |
D/D |
(560) |
105,785 |
|
- |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,308 |
117,728 |
|
- |
|
Vanderhaegen Frederic |
EVP, Americas and Europe |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,308 |
188,244 |
|
- |
|
Stubblefield Michael |
President & CEO |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
99,004 |
1,286,822 |
|
- |
|
Eck Steven W |
SVP & Chief Accounting Officer |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,347 |
22,238 |
|
- |
|
Bramwell James |
EVP, Americas |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,308 |
104,821 |
|
- |
|
Henson Meghan |
EVP, Chief HR Officer |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,185 |
40,984 |
|
- |
|
Lewis Sheri |
EVP, Global Ops & Supply Chain |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,185 |
76,588 |
|
- |
|
Couturier Christophe |
EVP, AMEA |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,138 |
103,508 |
|
- |
|
Szlosek Thomas A |
EVP & CFO |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
22,339 |
106,893 |
|
- |
|
Sahin Kitty |
EVP, Strategy&Corp Development |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,185 |
38,875 |
|
- |
|
Miller Justin |
EVP & General Counsel |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,138 |
106,345 |
|
- |
|
Brophy Gerard |
EVP, Biopharma Production |
|
2023-02-23 |
4 |
D |
$24.59 |
$46,549 |
D/D |
(1,893) |
97,420 |
|
- |
|
Vanderhaegen Frederic |
EVP, Americas and Europe |
|
2023-02-23 |
4 |
D |
$24.59 |
$5,238 |
D/D |
(213) |
167,936 |
|
- |
|
534 Records found
|
|
Page 4 of 22 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|